Funds with similar focus
|RoseRock||United States, Bryan|
|The MasterCard Foundation||Canada, Toronto|
|LSP BioVentures||United States, Cambridge|
|China Reinsurance Group||China, Beijing|
|MGM Studios||United States, Beverly Hills|
|Beijing Huadian Shidai Technology Development||China, Beijing|
|Hangzhou Yongyuan||China, Hangzhou|
|Tibet Kexin Venture Investment Partnership (L.P.)||China, Lhasa|
|Beijing Zhiyun Asset Management||China, Beijing Shi|
|Ai Hexin Touzi||China, Shenyang|
|$50M||01 Jul 2021||China, Hong Kong Island|
|$107M||11 Jan 2021||Cambridge Massachusetts United States|
|$50M||07 Jan 2021||Cambridge Massachusetts United States|
|$10M||30 Oct 2020||California Los Angeles United States|
|$260M||24 May 2018||California San Francisco United States|
|$300M||21 May 2018||California United States|
|$66M||16 May 2018||Cambridge Massachusetts United States|
|$117M||27 Mar 2018||China Shanghai|
Rent the Runway
|$20M||09 Mar 2018||New York United States|
– NEX, a motion entertainment startup, raised $25m funding.
– The round was led by Blue Pool Capital and joined by Samsung Ventures, SparkLabs and Susquehanna.
– It brings NEX to a valuation of $100m.
– The company is building motion entertainment – content that encourages physical movement.
– FogPharma announced the completion of a $107m Series C financing round.
– The round was led by venBio Partners with participation from new investors Cormorant Asset Management, Farallon Capital Management, Invus, funds and accounts advised by T. Rowe Price Associates, Inc.; HBM Healthcare Investments, Casdin Capital, and PagsGroup.
– Existing investors, including GV, 6 Dimensions Capital, Deerfield Management and Blue Pool Capital also participated in the oversubscribed round.
– FogPharma’s proprietary hyperstabilized α-helical peptides (Helicon™ peptides) are a new class of therapeutics that combine the targeting strength and specificity of antibodies with the broad tissue distribution, intracellular target engagement and oral dosing optionality of small molecules.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.